In Lancet Oncology this week, researchers in China report on the efficacy of gefitinib as a maintenance therapy for patients with locally advanced or metastatic non-small-cell lung cancer. The team randomly assigned 296 patients to receive either gefitinib or placebo, and found that progression-free survival was significantly longer with gefitinib. "Maintenance treatment with gefitinib significantly prolonged progression-free survival compared with placebo in patients from east Asia with advanced NSCLC who achieved disease control after first-line chemotherapy," the team writes. "Clinicians should consider these data when making decisions about maintenance treatment in such patients."
Also in Lancet Oncology this week, researchers in the UK report the results of a study of focal therapy for the treatment of localized unifocal and multifocal prostate cancer. The team recruited 42 men with low-risk to high-risk localized prostate cancer and treated them with focal therapy using high-intensity focused ultrasound. After treatment, only one man was admitted to the hospital for acute urinary retention, and nine men had self-resolving, mild to moderate, intermittent dysuria, the team says. Further, median overall International Index of Erectile Function-15 scores were similar at baseline and 12 months after treatments, as were the median scores for intercourse satisfaction, sexual desire, and overall satisfaction. "Focal therapy of individual prostate cancer lesions, whether multifocal or unifocal, leads to a low rate of genitourinary side-effects and an encouraging rate of early absence of clinically significant prostate cancer," the authors write.